Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the female infertility market size evolved in recent years?

In recent times, there has been consistent growth in the female infertility market, with its size projected to increase from $1.79 billion in 2024 to about $1.87 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The previous growth in this market can be traced back to factors such as the rising trend of women choosing to have children later in life, evolving lifestyle changes, increased government interventions, a growing aged population, and an upturn in assisted reproductive technology (ART) treatments.

What are the predictions for the female infertility market size in the coming years?

Over the coming years, significant progress is anticipated in the female infertility market as it is projected to expand to $2.19 billion in 2029, with a compound annual growth rate (CAGR) of 4.1%. The projected growth for this period can be associated with a heightened awareness of reproductive health issues, a growing count of polycystic ovary syndrome cases, increased instances of uterine anomalies, a rise in genetic disorders prevalence, and escalating obesity rates. The upcoming trends during the forecast period are likely to encompass developments in preimplantation genetic examination, technological progress, the inception of pioneering diagnostic technologies, advancements in fertility preservation, and the increasing use of telemedicine.

Get your female infertility market report here!

https://www.thebusinessresearchcompany.com/report/female-infertility-global-market-report

What key factors are fueling the growth of the female infertility market?

Going forward, the surge in infertility rates is forecasted to stimulate the expansion of the female infertility market. Infertility is defined as the failure to become pregnant after one year of regular, unprotected sex. The rise in infertility rates is attributed to delayed childbearing, lifestyle alterations, environmental pollutants, escalating obesity, and increased stress levels. To deal with and manage hormonal, medical, or structural issues that affect fertility, female infertility treatment is necessary. This not only improves the chances of becoming pregnant but also prevents long-term infertility. For example, as stated by the Human Fertilization and Embryology Authority, a non-departmental public body in the UK, in July 2024, effectively 77,000 fresh and frozen embryo transfer IVF cycles were carried out for 52,500 patients in the country’s licensed fertility clinics in 2022. More than 90% of these patients underwent treatment with a partner, involving almost 100,000 individuals. As a result, the escalating prevalence of infertility is driving the expansion of the female infertility market.

How is the global female infertility market divided into key segments?

The female infertility market covered in this report is segmented –

1) By Treatment: Clomiphene Citrate, Gonadotropins, Metformin, Letrozole, Bromocriptine

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Clomiphene Citrate: Oral Clomiphene Citrate, Injectable Clomiphene Citrate

2) By Gonadotropins: Recombinant Gonadotropins, Urinary Gonadotropins, Human Chorionic Gonadotropin (hCG)

3) By Metformin: Immediate-Release Metformin, Extended-Release Metformin

4) By Letrozole: Oral Letrozole Tablets, Injectable Letrozole

5) By Bromocriptine: Oral Bromocriptine Tablets, Intranasal Bromocriptine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20787&type=smp

Who are the key firms paving the way for growth in the female infertility market?

Major companies operating in the female infertility market are Pfizer Inc., Roche Holding AG, Merck And Co. Inc, Bayer AG, Sanofi S.A., AstraZeneca Plc, Abbott Laboratories, Mayo Clinic, Teva Pharmaceutical Industries Ltd, Commonwealth Serum Laboratories Ltd, Organon Theramex, Juniper Reproductive Health Ltd., Sumitomo Pharma, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Co., Mankind Pharma, Kissei Pharmaceutical Co Ltd, ASKA Pharmaceutical Co. Ltd., Fuji Pharma Co. Ltd., ARMC IVF, Zydus Cadila Healthcare, IBSA Institut Biochimique, Oxolife, Ava AG, Hernova Lifesciences Holdings Ltd

What key trends are currently impacting the female infertility market’s development?

Major companies operating in the female infertility market are focusing on developing innovative products, such as non-invasive diagnostic tests, to gain a competitive edge in the industry. A non-invasive diagnostic test is a medical test that detects conditions or diseases without requiring surgery or penetration of the body. For instance, in August 2024, Heranova Lifesciences, a US-based biotech company, launched an early access program for HerResolve, a non-invasive diagnostic test for endometriosis. Endometriosis affects about 200 million women worldwide, causing symptoms like infertility, pain, and bleeding. For many women, an accurate diagnosis takes an average of 7-10 years from the onset of symptoms, mainly due to the varied symptom presentation and the invasive nature of the most reliable diagnostic method, exploratory laparoscopic surgery. HerResolve potentially reduces this diagnostic delay from years to months, leading to better patient and healthcare outcomes. HerResolve aims to shorten this timeline significantly, improving patient care and outcomes.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20787

What regions are contributing significantly to the growth of the female infertility market?

Europe was the largest region in the female infertility market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the female infertility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Female Fertility And Pregnancy Rapid Test Global Market Report 2025

https://thebusinessresearchcompany.com/report/female-fertility-and-pregnancy-rapid-test-global-market-report

Pregnancy Test Kits Global Market Report 2025

https://thebusinessresearchcompany.com/report/pregnancy-test-kits-global-market-report

Assisted Reproductive Technology Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/assisted-reproductive-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: